Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
Company

Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report

Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
CompanyDrug

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors

Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility
CompanyDeals

Shouyao Holdings Unveils RMB787 Million Investment in Beijing BioPark R&D and GMP Facility

Biokin's BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
CompanyDrug

Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply
Company

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply

CentryMed's CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors
CompanyDrug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Pfizer's Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
CompanyDrug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
CompanyDrug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Grand Pharma's AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
CompanyMedical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler
CompanyMedical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Roche's Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics
Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics